Fact CheckerSign in

NCT07467993RecruitingPhase 2

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)

Source: ClinicalTrials.gov · Last updated 29 Jul 2026

Brief summary (registry, in English)

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
142 (estimated)
First submitted
9 Mar 2026
Start date
16 Mar 2026
Primary completion date
29 Jul 2027
Lead sponsor
Novartis Pharmaceuticals
NCT number
NCT07467993

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 142
  • From 16 Mar 2026 to the primary completion date, 29 Jul 2027
  • 15 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) at screening)
  • History of treatment resistance to antipsychotic medications defined as inadequate response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia
  • Participants who need to be treated with drugs that are known to be moderate and strong CYP3A4 inhibitors and inducers will be excluded
  • Participants taking a long-acting injectable antipsychotic could not have received a dose of medication in the last 12 weeks (24 weeks for INVEGA TRINZA®) before baseline
    • Other protocol-defined inclusion/exclusion criteria may apply

Who the study is looking for

  • Participant is aged 18 to 65 years, inclusive, at screening
  • Participant is capable of providing informed consent
  • Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT)
  • Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements
  • Participant is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening
    • The participant requires hospitalization for this acute exacerbation or relapse of symptoms
    • If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening
  • Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items:
    • Item 1 (P1; delusions)
  • Item 2 (P2; conceptual disorganization)
  • Item 3 (P3; hallucinatory behavior)
  • Item 6 (P6; suspiciousness/persecution)

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (15)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Novartis Investigative Site
Coordinator of this site? Confirm its status
HaskovoBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
KazanlakBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
LovechBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
PlovdivBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
SlivenBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
SofiaBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
Veliko TarnovoBulgariaRecruiting
Novartis Investigative Site
Coordinator of this site? Confirm its status
VratsaBulgariaRecruiting
Pillar Clinical Research LLC
Coordinator of this site? Confirm its status
BentonvilleUnited StatesRecruiting
Uptown Research Institute, LLC
Coordinator of this site? Confirm its status
ChicagoUnited StatesRecruiting
Pillar Clinical Research LLC
Coordinator of this site? Confirm its status
ChicagoUnited StatesRecruiting
CenExel iResearch
Coordinator of this site? Confirm its status
DecaturUnited StatesRecruiting
Segal Institute for Clinical Research
Coordinator of this site? Confirm its status
MiamiUnited StatesRecruiting
CNRI-Los Angeles, LLC
Coordinator of this site? Confirm its status
Pico RiveraUnited StatesRecruiting
Arch Clinical Trials, LLC
Coordinator of this site? Confirm its status
St LouisUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.